X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/fda-rejects-defenders-motion-sickness-nasal-gel-candidate#:~:text=A%20nasal%20gel%20version%20of%20the%20motion%20sickness%20drug%20scopolamine,and%20vomiting%20induced%20by%20motion.
https://www.globenewswire.com/news-release/2024/01/30/2820312/0/en/Defender-Pharmaceuticals-Receives-Complete-Response-Letter-from-the-U-S-Food-and-Drug-Administration-for-its-Intranasal-Scopolamine-DPI-386-New-Drug-Application-for-the-Prevention-.html
https://www.globenewswire.com//news-release/2023/10/24/2765559/0/en/Defender-Pharmaceuticals-Announces-Collaboration-with-NASA-on-Two-Phase-2-Clinical-Trials-Investigating-DPI-386-s-Ability-to-Mitigate-G-transition-Induced-Motion-Sickness-and-Enhan.html
https://www.globenewswire.com//news-release/2023/09/26/2749419/0/en/FDA-Accepts-Defender-Pharmaceuticals-New-Drug-Application-for-Intranasal-Scopolamine-Gel.html
https://www.globenewswire.com/news-release/2023/08/10/2722946/0/en/Defender-Pharmaceuticals-Phase-3-Motion-Sickness-Trial-Results-Selected-for-Presentation-at-2023-Military-Health-System-Research-Symposium-MHSRS.html
https://www.globenewswire.com/news-release/2023/07/31/2715262/0/en/Defender-Pharmaceuticals-Announces-Exclusive-License-Agreement-with-the-U-S-Army-for-the-Development-of-Products-to-Treat-Tropical-Diseases.html
https://www.globenewswire.com/news-release/2023/07/26/2711490/0/en/Defender-Pharmaceuticals-Announces-Submission-of-New-Drug-Application-to-FDA-with-Intranasal-Scopolamine-for-Prevention-of-Nausea-and-Vomiting-Induced-by-Motion-in-Adults.html
Market Place
Share 
